Alexander Disease Clinical Trials 2023

Alexander Disease Clinical Trials 2023

Alexander Disease research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in alexander disease clinical trials today.

Alexander Disease Clinical Trials

Here are the 0 most popular medical studies for alexander disease

Popular filter options for alexander disease trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to alexander disease

What are the top hospitals conducting alexander disease research?

Advancements in medical research are not just limited to well-known conditions; lesser-known diseases also receive attention from top-notch hospitals. One such condition is Alexander disease, a rare and progressive neurological disorder that primarily affects children. In Palo Alto's Lucile Packard Children's Hospital Stanford, researchers are currently conducting the first-ever clinical trial for Alexander disease, marking an important step forward in understanding and potentially treating this debilitating illness. Similarly dedicated to finding solutions for this disorder, IONIS Investigative Sites located in Atlanta and Chicago are also actively recruiting children for their own ongoing trials. These sites have joined forces with other leading institutions like Mass General Hospital in Boston and IONIS Investigative Site in Boston to collectively explore possible interventions against Alexander disease. With each hospital initiating their first recorded trial in 2021, these efforts signify a collaborative commitment among experts nationwide to improve the lives of those affected by this rare condition through cutting-edge research and innovative treatments.

Alexander disease may be relatively unfamiliar to many individuals due to its rarity; however, the dedication showcased by these hospitals represents the unwavering drive within the medical community to unravel mysteries surrounding even the most obscure illnesses. By bringing together expertise from different locations across America, they demonstrate how collaboration can lead to significant breakthroughs that hold promise for patients fighting against challenging conditions like Alexander disease.

Which are the best cities for alexander disease clinical trials?

When it comes to clinical trials for Alexander disease, several cities emerge as leading hubs of research. Atlanta, Georgia; Boston, Massachusetts; Vancouver, British Columbia; Philadelphia, Pennsylvania; and Palo Alto, California are at the forefront with their active trials focused on studying ION373 and other potential treatments. With three active trials in each of these cities except for Palo Alto with one trial, individuals affected by Alexander disease have access to cutting-edge research that aims to improve outcomes and advance our understanding of this rare neurological disorder.

Which are the top treatments for alexander disease being explored in clinical trials?

Researchers are actively investigating potential treatments for Alexander disease, with one standout contender taking the lead in clinical trials. ION373 has emerged as a promising option, currently being explored in one active trial dedicated to this rare neurological disorder. Since its initial listing in 2021, it has already made an impact on the field of Alexander disease research by being the sole treatment under investigation thus far. As scientists delve deeper into understanding this complex condition and identifying effective therapies, ION373 shines as a beacon of hope for patients and their families affected by Alexander disease.

What are the most recent clinical trials for alexander disease?

In the realm of Alexander disease research, a recent clinical trial has emerged as a beacon of hope. Known as ION373, this Phase 3 study focuses on evaluating its efficacy in treating alexander disease. With its availability since June 1, 2021, this trial represents an important step forward in understanding and potentially improving the lives of individuals affected by this rare neurological disorder. As researchers continue to delve into innovative treatments for alexander disease, the results from ION373 hold promise for patients and their families eagerly awaiting advancements in medical science.

What alexander disease clinical trials were recently completed?

Recently completed clinical trials for Alexander disease, a rare genetic disorder, have made important strides in advancing our understanding and potential treatments. While there are currently no specific clinical trials that have been recently completed for this condition, ongoing research efforts are underway to explore new avenues for diagnosis and therapy development. Researchers remain committed to uncovering more about Alexander disease and working towards better options for patients affected by this challenging condition.